SPEAKING
image description

Clinically Speaking Issue 21: April 2026

Smarter Pharmacy Care: Lower Costs, Better Outcomes

Our clinically-driven pharmacy care model reduces specialty drug costs by optimizing the drug mix. This is because comparable, lower cost, non-specialty drugs, biosimilars, and other therapies are recommended if clinically appropriate.

  • 90% generic dispensing rate. Does your PBM prefer brands over generics?
    • 64% therapeutic switch rate.

Dose Optimization

  • 300+ medications targeted to ensure lower pill burden/-pill count and minimize waste (drug and financial).

Retrospective Drug Utilization Review

  • Over 150 specialty drugs targeted for enhanced oversight throughout therapy.
In Case You Missed It:

Infusion Therapy Management
We are excited to announce the launch of our Infusion Therapy Management solution, which delivers increased pricing visibility and cost savings by shifting infusion therapies to be covered under the pharmacy benefit rather than the medical benefit. This new program produces up to 10%+ in savings for plan sponsors, utilizing our Medication Optimization (MO) operating model to expand clinical oversight on high-cost infusion treatments. Learn more about our Infusion Therapy Management solution in our press release below.

​Clinically Speaking Episode 2: “Pharmacy is Finally Having a ‘Moment,’ and Why That Matters”
Clinically Speaking Episode 2: “Pharmacy is Finally Having a ‘Moment,’ and Why That Matters” is out now! Hosted by Patrick Di Chiro, this episode features Chronis Manolis, former Senior VP of Pharmacy and Chief Pharmacy Officer, University of Pittsburgh Medical Center, Insurance Service Division, and current Senior Advisor to UPMC. As healthcare becomes more complex and costly, pharmacy is stepping into a more critical and strategic role. In this informative conversation, Chronis shares his perspective on the current state of pharmacy care, why pharmacy is gaining greater importance across healthcare, and discusses future opportunities to improve health outcomes while managing costs.

National Association of Chain Drug Stores (NACDS) Annual Meeting
​​EmpiRx Health was thrilled to attend the National Association of Chain Drug Stores (NACDS) Annual Meeting, in April in Palm Beach, FL! This event brought together industry leaders and decision makers shaping the future of healthcare and pharmacy. The meeting also offered valuable opportunities for meaningful conversations through strategic sessions designed to foster collaboration and build new partnerships.

Clinical Success Story

Patient: 61-year-old male
Diagnosis: Rheumatoid arthritis (RA)
Population Health Management Engine Identified: Therapy optimization opportunity.

•  The patient was prescribed a new therapy, Enbrel SureClick® 50 mg/ml, for the treatment of Rheumatoid Arthritis (RA). Upon review, our Care Team identified that the patient had not previously trialed first‑line treatment options.

•  Our in‑house pharmacist reached out to the prescriber to review the patient’s previous therapies and potential contraindications, and to discuss appropriate first‑line alternatives for RA treatment. It was confirmed that the patient did not have a contraindication to Leflunomide, and the prescriber agreed to change the therapy.

•  The member was counseled on the alternative treatment and prescribed Leflunomide 20 mg tablets. This intervention resulted in improved clinical outcomes and measurable cost savings.
​​​​
Annual Clinical Savings for the Plan Sponsor: $86,504